Issue link: https://www.e-digitaleditions.com/i/1521797
30 June 2024 Inhalation 39. Tiozzo Fasiolo, L., et al. Opportunity and chal- lenges of nasal powders: Drug formulation and deliv- ery. Eur J Pharm Sci 113, 2-17 (2018). 40. Murdande, S. B., et al. Aqueous solubility of crystalline and amorphous drugs: Challenges in mea- surement. Pharm Dev Technol 16, 187-200 (2011). 41. Kawakami, K., et al. Impact of degree of super- saturation on the dissolution and oral absorption behaviors of griseofulvin amorphous solid disper- sions. J Drug Deliv Sci Technol 56, 101172 (2020). 42. Dalpiaz, A., et al. Nasal chitosan microparticles target a zidovudine prodrug to brain HIV sanctuar- ies. Antiviral Res 123, 146-157 (2015). 43. Rassu, G., et al. Solid microparticles based on chitosan or methyl-β-cyclodextrin: A first formula- tive approach to increase the nose-to-brain transport of deferoxamine mesylate. JCR 201, 68-77 (2015). 44. Sosnik, A., et al. Mucoadhesive polymers in the design of nano-drug delivery systems for administra- tion by non-parenteral routes: A review. Prog Polym Sci 39, 2030-2075 (2014). 45. Mašková, E., et al., Hypromellose—A traditional pharmaceutical excipient with modern applications in oral and oromucosal drug delivery. JCR 324, 695- 727 (2020). 46. Bartkowiak, A., et al. Surface and swelling prop- erties of mucoadhesive blends and their ability to release fluconazole in a mucin environment. Colloids Surf B Biointerfaces 172, 586-593 (2018). 47. Henriques, P., et al. Amorphous nasal powder advanced performance: In vitro/ex vivo studies and correlation with in vivo pharmacokinetics. J Pharm Investig 2023 1-20 (2023). 48. Jug, M., et al. An overview of in vitro dissolution/ release methods for novel mucosal drug delivery sys- tems. J Pharm Biomed Anal 147, 350-366 (2018). 49. Sun, D. D., et al. Evolution of supersaturation of amorphous pharmaceuticals: e effect of rate of supersaturation generation. Mol Pharm 10, 4330- 4346 (2013). Patrícia Henriques, PhD, performed her PhD studies at the Faculty of Pharmacy, University of Coimbra, Pólo das Ciências da Saúde, Azinhaga de Santa Comba, 3000-548 Coimbra, Portugal and currently is a Sci- entist at Hovione, R&D, Inhalation and Advanced Drug Development, Hovione FarmaCiencia SA, Lis- bon, Portugal, pdhenriques@hovione.com. Slavomíra Doktorovová, PhD, is a Senior Scientist, R&D, Oral Drug Product Development, Hovione FarmaCiencia SA, Lisbon, Portugal, sdoktorovova@hovione.com, www.hovione.com. 23. Jiang, G., et al. Anthrax vaccine powder formu- lations for nasal mucosal delivery. J Pharm Sci 95, 80-96 (2006). 24. Wang, S. H., et al. Stable dry powder formula- tion for nasal delivery of anthrax vaccine. J Pharm Sci 101, 31-47 (2012). 25. Sacchetti, C., et al. Caffeine microparticles for nasal administration obtained by spray drying. Int J Pharm 242, 335-339 (2002). 26. Russo, P., et al. Chimeral agglomerates of micro- particles for the administration of caffeine nasal pow- ders. J Drug Deliv Sci Technol 14, 449-454 (2004). 27. Russo, P., et al. Primary microparticles and agglomerates of morphine for nasal insufflation. J Pharm Sci 95, 2553-2561 (2006). 28. Balducci, A. G., et al. Antidiuretic effect of des- mopressin chimera agglomerates by nasal adminis- tration in rats. Int J Pharm 440, 154-160 (2013). 29. Giuliani, A., et al. In vivo nose-to-brain delivery of the hydrophilic antiviral ribavirin by microparticle agglomerates. Drug Deliv 25, 376-387 (2018). 30. Colombo, P., et al. Powder for nasal administra- tion of drugs. US20050019411A1 (2005), https:// patents.google.com/patent/US20050019411A1/en. 31. Ziaee, A., et al. Spray drying of pharmaceuti- cals and biopharmaceuticals: Critical parameters and experimental process optimization approaches. Eur J Pharm Sci 127, 300-318 (2019). 32. Tiozzo Fasiolo, L., et al. Opportunity and chal- lenges of nasal powders: Drug formulation and deliv- ery. Eur J Pharm Sci 113, 2-17 (2018). 33. FDA. Onzetra Xsail—Sumatriptan nasal powder. https://www.accessdata.fda.gov/drugsatfda_docs/ nda/2016/206099Orig1s000TOC.cfm (2016). 34. Drug Approval Package: BAQSIMI. https:// www.accessdata.fda.gov/drugsatfda_docs/nda/2019/ 210134Orig1s000TOC.cfm. 35. Henriques, P., et al. Spray dried powders for nasal delivery: Process and formulation considerations. Eur Journal Pharm Biopharm 176, 1-20 (2022). 36. Chen, J. Z., et al. In vitro assessment of an ide- alized nose for nasal spray testing: Comparison with regional deposition in realistic nasal replicas. Int J Pharm 582, 119341 (2020). 37. Chen, J. Z., et al. In vitro regional deposition of nasal sprays in an idealized nasal inlet: Comparison with in vivo gamma scintigraphy. Pharm Res 39, 3021-3028 (2022). 38. Copley Scientific. Realistic roat and Nasal Cast Models—Alberta Idealised Nasal Inlet (AINI). https://www.copleyscientific.com/ inhaler- testing/realistic-throat-and-nasal-models/ alberta-idealised-nasal-inlet-aini.